Kane Biotech Inc. (TSXV: KNE)

Market Cap	15.81M
Revenue (ttm)	757.11K
Net Income (ttm)	4.83M
Shares Out	137.51M
EPS (ttm)	0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,000
Open	0.110
Previous Close	0.110
Day's Range	0.110 - 0.115
52-Week Range	0.060 - 0.170
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 28, 2024

About Kane Biotech

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: KNE

Financial Performance

In 2023, Kane Biotech's revenue was 148,980, a decrease of -4.95% compared to the previous year's 156,733. Losses were -5.03 million, 29.4% more than in 2022.